Understanding how the STK25 kinase helps control tumor growth
Defining the tumor suppressive mechanism of the kinase STK25
This study is looking at how a protein called STK25 helps control cell growth and prevent tumors by interacting with important pathways in our cells, and it could lead to new ways to treat cancer for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11015784 on NIH RePORTER |
What this research studies
This research investigates the role of the STK25 kinase in regulating cell growth and tumor suppression by examining its interactions with two important signaling pathways: mTOR and Hippo. The study aims to uncover how STK25 influences these pathways to prevent abnormal cell proliferation and tumor development. By using advanced techniques, the researchers will explore the mechanisms through which STK25 affects mTOR signaling, which is crucial for maintaining cellular balance. Patients may benefit from insights gained about tumor growth regulation and potential new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are individuals diagnosed with cancers, particularly those related to dysregulation of the mTOR and Hippo pathways.
Not a fit: Patients with non-cancerous conditions or those whose tumors are not influenced by the mTOR or Hippo pathways may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer treatment by enhancing our understanding of tumor suppression mechanisms.
How similar studies have performed: Previous research has shown promising results in understanding the roles of mTOR and Hippo pathways in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Ho, Rachel Xi-Yeen — Boston University Medical Campus
- Study coordinator: Ho, Rachel Xi-Yeen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.